Site icon Impactiviti

Impactiviti Daily 040810



Great news for hepatitis C treatment (and Vertex) – Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were retreated with the standard regimen, according to researchers at the Duke Clinical Research Institute (DCRI)more

Teva gets approval to market generic versions of two key Merck cardio drugs (Cozaar and Hyzaar).

Sanofi makes a long-term investment into a cool-sounding diabetes treatment (pre-Phase 1).

Is Nuvaring a pinata for plaintiff’s attorneys? – Merck’s Nuvaring contraceptive appears to be headed for the same fate as Bayer’s Yaz pill and Johnson & Johnson’s Ortho Evra contraceptive patch: It’s becoming a pinata for plaintiffs’ lawyers who allege the device is more dangerous than older, equally effective products on the marketmore


eMarketing/PR– We can recommend best-in-class partners/agencies for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


Social Media – Nine things Pharma should learn about Social Media from Dennis Urbaniak (of Sanofi-Aventis US). And, the finalists for the first Dosie Awards are announced.


Did you know that Niagara Falls once ran dry? True!


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)


Exit mobile version